1. Canada Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Tetra Bio-Pharma Inc.

Tetra Bio-Pharma Inc.

OOTC:TBPMQ
0.00
USD
0.00
(0.00%)
-0.07EPS
19.60MMarket Cap
2009 Y
2010 Y
2011 Y
2012 Y
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
TTM
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
-0.05
-0.04
-0.03
-0.02
-0.08
-0.01
-0.01
-0.01
-0.06
-0.05
-0.08
-0.1
-0.12
-0.09
Free Cash Flow per Basic Share
-0.03
-0.04
-0.08
-0.04
-0.01
-0.01
- -
-0.01
-0.04
-0.07
-0.09
-0.08
-0.06
-0.02
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
0.04
- -
0.1
0.09
0.01
0.01
- -
0.02
0.09
0.13
0.12
0.08
- -
-0.01
Tangible Book Value per Share
0.04
- -
0.1
0.09
0.01
0.01
- -
0.01
0.02
0.08
0.01
- -
- -
-0.01
Basic Weighted Avg Shares
8
11
19
24
26
29
55
65
108
146
188
258
446
413
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
- -
-1
- -
-1
-2
- -
-1
-1
-6
-8
-15
-26
-52
-39
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Working Capital
- -
- -
1
- -
- -
- -
- -
1
2
12
1
-3
-1
-7
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
- -
- -
2
2
- -
- -
- -
1
11
21
25
23
- -
-6
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
-152.13
-252.02
-43.39
-24.54
-175.31
-217.38
- -
- -
-98.72
-47.26
-67.12
-112.09
-456.91
- -

Capital Structure

CAD

•

in mil. unless spec.
Feb'22
May'22
Aug'22
ST Debt
3
2
2
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
415
423
423
Market Capitalization
36
25
26

Working Capital

CAD

•

in mil. unless spec.
Feb'22
May'22
Aug'22
Total Current Assets
7
4
2
Cash, Cash Equivalents & STI
4
2
- -
Accounts Receivable, Net
3
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
8
8
9
Payables & Accruals
5
5
7
ST Debt
3
2
2
Deferred Revenue
- -
- -
- -

Growth Rates

CAD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-29.48%
133.78%
-98.9%
Free Cash Flow
84.82%
125.53%
21.29%
Net Income, GAAP
116.75%
170.61%
97.06%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

CAD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2020
- -
- -
- -
- -
- -
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

CAD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2020
-0.02
-0.02
-0.02
-0.04
-0.1
2021
-0.03
-0.02
-0.01
-0.08
-0.12
2022
- -
-0.01
-0.01
- -
- -

Quarterly Dividends Per Share

CAD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2020
- -
- -
- -
- -
- -
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Guy Chamberland Master Herbal
Full Time Employees
33
Sector
Health technology
Industry
Pharmaceuticals: major
Address
2316 St. Joseph Boulevard Orleans ON Canada K1C 1E8
IPO Date
Jun 22, 2011
Website
tetrabiopharma.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Tetra Bio-Pharma Inc. (TSX Venture: TBP) develops cannabinoid-derived biopharmaceuticals targeting inflammation, pain, ophthalmology, and oncology indications through clinical programs and prescription drug candidates for patients and healthcare providers. The company offers a pipeline of cannabinoid-based products including QIXLEEF, a botanical THC-CBD therapy for therapeutic uses; CAUMZ; PPP004 for painful dry eye and uveitis; REDUVO, a dronabinol soft gel capsule for chemotherapy-induced nausea, vomiting, and HIV-related weight loss; REBORN1 for breakthrough cancer pain and oral opioid alternatives; PLENITUDE for cancer-related pain; ARDS-003 for sepsis and acute respiratory distress syndrome prevention; SERENITY for cancer cachexia; and HCC011 for hepatocellular carcinoma, alongside veterinary products and natural health formulations; it employs advanced delivery systems, patented mechanisms, and rigorous clinical trials to meet pharmaceutical standards. Founded in 2008 and headquartered in Orleans, Ontario, Canada, with approximately 33 employees and subsidiaries such as Phyto Pain Pharma Inc., Panag Pharma Inc., and a former Australian entity, Tetra Bio-Pharma operates primarily in North America with past clinical trial partnerships in Australia. Recent major developments include a 2019 acquisition of Panag Pharma to bolster ophthalmic pain formulations; partnerships with Avicanna, Cellvera Global Holdings for ARDS-003/favipiravir COVID-19 combo, Ovensa for glioblastoma nanomedicines, and Cannvalate for Australian trials; financing such as C$6 million from Alpha Blue Ocean in 2019 and up to C$4.5 million Quebec loan; regulatory milestones like Health Canada NDS review for REDUVO, EMA orphan drug opinion for QIXLEEF, and U.S. mid-stage trial shipments; followed by a voluntary bankruptcy filing under Canada's Bankruptcy and Insolvency Act on August 1, 2023, with Houle Roy S.A. as trustee after Ontario Securities Commission rejection of a management cease trade order precluded further financing, leading to halted operations, delisting from TSX Venture, and OTC trading as TBPMQ/TBPMF.